Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
The Pharma Letter17h
EMA annual report 2024
At its March meeting, the European Medicines Agency’s management board adopted the EMA’s annual report for 2024. This ...
PharmiWeb4d
STADA’s growth journey continues in 2024 - Significant increase in sales and profits - Growing ahead of the market
STADA, a leading healthcare and pharmaceutical company in Consumer Healthcare, Generics and Specialty pharmaceuticals, continued its profitable growth journey in 2024. STADA again outperformed the ...
Biocon shares in focus after successful results of Yesintek in Phase 3
Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the ...
Medical Dialogues6d
Phase 3 study comparing Yesintek with Stelara in adult patients with chronic plaque psoriasis shows positive results: Biocon Biologics
Bengaluru: BioconBiologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd. has announced ...
CNBCTV187d
Biocon Biologics’ biosimilar Yesintek shows positive phase 3 results for psoriasis treatment
The findings, which confirm the biosimilar’s efficacy and safety profile compared to Stelara, are being presented at the 2025 ...
Le Lézard7d
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintektm Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced the successful results of a pivotal Phase 3, ...
Center for Biosimilars7d
The Top 5 Biosimilar Articles for the Week of March 3
Number 5: The approvals for Celltrion's denosumab-bmwo (Stoboclo and Osenvelt) mark the third FDA green light for a ...
Pharmabiz9d
US FDA approves Celltrion’s Stoboclo and Osenvelt biosimilars referencing Prolia and Xgeva
US FDA approves Celltrion’s Stoboclo and Osenvelt biosimilars referencing Prolia and Xgeva: Jersey City, New Jersey Wednesday, March 5, 2025, 18:00 Hrs [IST] Celltrion, a leadin ...
The Manila Times11d
Celltrion receives U.S. FDA approval for STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) biosimilars referencing PROLIA® and XGEVA®
STOBOCLO ® (denosumab-bmwo) and OSENVELT ® (denosumab-bmwo) are approved by FDA for all indications of reference products ...
Business Wire11d
Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
“We have a longstanding and productive partnership with Amneal, and we are pleased to be advancing these two important products to the U.S. biosimilar market. We remain focused on our globalization ...